1. Introduction {#sec1}
===============

*Candida albicans* is an opportunistic fungus that infects the mucosae of oral and vaginal cavities \[[@B1]\]. Vulvovaginal candidiasis (VVC) is among the most common infections that affect women of childbearing age \[[@B2]\]. Clinical strains of*C. albicans* possess an array of virulence genes that directly influence the pathogenesis of VVC, including genes responsible for phenotypic switching \[[@B3]\],*HWP1* (hyphal wall protein 1) \[[@B4]\],*ALS* (agglutinin-like sequence) \[[@B5]\],*SAP* (secreted aspartyl proteases) \[[@B6]\],*PL* (phospholipases) \[[@B7]\], and*LIP* (lipases) \[[@B8]\]. The aspartyl proteases, phospholipases, and lipases are involved in the breakdown of cell membranes in host epithelia, which promotes colonization and invasion \[[@B9]\].

The increase of*C. albicans* resistant to antifungal agents, mainly to azoles, is a serious health problem and hampers the treatment of VVC. The mechanisms responsible for resistance to azoles include overexpression of*CDR1* and*CDR2* from the ABC transporter family and*MDR1* which encodes a multidrug efflux pump. Mutations in*ERG5* and*ERG11*, which cause alterations in C22-desaturase and sterol 14*α*-demethylase, respectively, are also associated with azole resistance \[[@B10]\].

The expression of*ALS* and*SAP* gene families in*C. albicans* of vaginal origin has recently been studied \[[@B11], [@B12]\]. Likewise, the gene expression patterns of the*LIP* and*PL* family, which are associated with the formation of biofilm during infection, have been studied \[[@B13]\]. However, the expression patterns of*ALS*,*HWP1*,*SAP*,*LIP*, and*PLB* in association with azole resistance genetic determinants have been less studied in strains of vaginal origin. In this work, to analyse the expression patterns of*ALS1--ALS3*,*HWP1*,*SAP1*,*SAP4--SAP6*,*LIP1--LIP10*,*PLB1*-*PLB2*,*CDR1*, and*MDR1*, we implemented an in vitro model of infection of human vaginal cells with*C. albicans* strains isolated from women with VVC.

2. Materials and Methods {#sec2}
========================

2.1. Patients Analysed and Sampling {#sec2.1}
-----------------------------------

Our study included a group of 200 women (ages 18--57) who attended the gynaecology department of public hospitals in the State of Mexico, Mexico, and presented characteristic symptoms of VVC (itching, burning, dysuria, and curd-like discharge). In this study, adult women with/without active sexual life were included. The exclusion criteria were as follows: patients with cervical cancer, being pregnant, being under antibiotic treatment, or having ingested antifungal drugs in the last 30 days. In addition, the patients informed if they had been previously exposed to azoles at least once in the last year as treatment for VVC. All participating women signed a letter of informed consent. The ethics committee of each hospital approved the study. Two samples were taken from the cervicovaginal cavity of each patient, using sterile swabs. The first was used to observe the presence of yeast, hyphae, or pseudohyphae by light microscopy. The second was incubated for 24 h at 37°C in brain heart infusion (BHI) medium (BD Bioxon, Cuautitlan Izcalli, State of Mexico, Mexico). After 24 h, the samples were incubated at 37°C in Sabouraud agar plates (BD Bioxon) with 50 *μ*g/mL chloramphenicol.

2.2. Identification of*C. albicans* {#sec2.2}
-----------------------------------

*C. albicans* strains were identified by the API 20 C Aux test (bioMerieux, Durham, NC, USA), germ tube test \[[@B11]\], and PCR amplification of ITS1 and ITS2 rRNA loci (the primers are shown in [Table 1](#tab1){ref-type="table"}) \[[@B14]\]. The DNA of the strains was extracted by boiling, as described by Paniagua-Contreras et al. \[[@B15]\]. The*C. albicans* strain B311 (ATCC 32354, ATCC, Manassas, VA, USA) was used as a positive control.

2.3. Antifungal Susceptibility {#sec2.3}
------------------------------

To test*C. albicans* antifungal susceptibility, we used diffusion disks impregnated with 25 *μ*g of fluconazole, 10 *μ*g of ketoconazole, and 100 U nystatin (HiMedia Laboratories, Mumbai, India). Antifungal susceptibility was established according to the interpretation criteria previously described ([Table 2](#tab2){ref-type="table"}) \[[@B16]\].

2.4. Detection of Genetic Virulence Markers and Azole Resistance Genes by PCR {#sec2.4}
-----------------------------------------------------------------------------

The primers and PCR conditions used were previously described: ALS1 and ALS3 \[[@B17]\], HWP1 \[[@B18]\], SAP1 \[[@B19]\], SAP4--SAP6 \[[@B20]\], LIP1--LIP10 and PLB1-PLB2 \[[@B13]\], and CDR1 and MDR1 \[[@B21]\] ([Table 1](#tab1){ref-type="table"}).

2.5. In Vitro Infection Model {#sec2.5}
-----------------------------

To study the expression of virulence markers and azole resistance genes, we used the A431 cell line (ATCC CRL-1555), which is derived from a vulvar epidermoid carcinoma. The growth conditions of the strains were previously reported \[[@B22], [@B23]\]. The A431 cell culture was inoculated with 50 *μ*L of phosphate-buffered saline (PBS) with 2 × 10^6^ *C. albicans*cells. The mixed cultures were incubated for 72 h at 37°C in 5% CO~2~. The culture medium was changed every 24 h.*C. albicans* (ATCC 32354) and*Staphylococcus epidermidis* (ATCC 35984) were used as positive and negative controls, respectively.

2.6. RNA Purification and cDNA Synthesis {#sec2.6}
----------------------------------------

After infection of A431 cells, the yeasts were harvested and suspended in 200 *μ*L of buffer Y1 (Qiagen, Hilden, Germany) with lyticase (50 U/10^7^ cells). Samples were incubated for 20 min at 30°C with gentle agitation to facilitate the formation of spheroplasts. Total RNA was purified on a robotic QIAcube workstation (Qiagen) using the RNeasy Mini Kit (Qiagen), following the manufacturer\'s instructions, including DNase treatment. The concentration and purity of total RNA were analysed on a NanoDrop spectrophotometer 2000 (Thermo Scientific, Waltham, MA, USA). cDNA was synthesized with the QuantiTect Reverse Transcription kit (Qiagen) according to manufacturer\'s instructions.

2.7. Amplification and Detection of the Azole Resistance and Virulence Genes {#sec2.7}
----------------------------------------------------------------------------

Amplification and detection of azole resistance and virulence genes were performed using real-time PCR with the Rotor-Gene SYBR Green PCR kit (Qiagen). The primer sequences used for the gene expression analysis are shown in [Table 1](#tab1){ref-type="table"}. The final volume of each reaction was 25 *μ*L, consisting of 12.5 *μ*L of SYBR Green Master Mix, 1 *μ*L of forward primer (1 *μ*M), 1 *μ*L of reverse primer (1 *μ*M), 2 *μ*L of cDNA (\~20 ng), and 8.5 *μ*L RNase-free water. Amplification conditions were 95°C for 5 min, 40 cycles at 95°C for 5 s, and combination alignment/extension at 60°C for 10 s. The amplification conditions for the positive and negative controls were the same as described above.

3. Results {#sec3}
==========

3.1. Identification of*C. albicans* and Antifungal Resistance Phenotypes {#sec3.1}
------------------------------------------------------------------------

*C. albicans* was identified in 19.5% (*n* = 39) of the samples and, in the remaining ones (80.5%, *n* = 161), bacteria such as*Escherichia coli*,*Klebsiella*spp.,*Staphylococcus aureus*, or*Staphylococcus epidermidis* were found.

All 39 isolates were sensitive to nystatin, whereas 97.4% (*n* = 38) and 94.9% (*n* = 37) were resistant to fluconazole and ketoconazole, respectively ([Table 3](#tab3){ref-type="table"}). Resistance to both azoles was found in 94.9% (*n* = 37) of the strains.

3.2. Detection of Virulence Markers and Azole Resistance Genes {#sec3.2}
--------------------------------------------------------------

All of the isolated strains (*n* = 39) were carriers of the*ALS1, SAP4*-*SAP6*,*LIP1*,*LIP2*,*LIP4*,*LIP6*,*LIP7*,*LIP9*,*LIP10,* and*PLB1*--*PLB2*genes. Other genes detected were*SAP1* in 94.8% (*n* = 37),*HWP1* (89.7%, *n* = 35),*ALS3* (35.8%, *n* = 14), and*CDR1* (66.6%, *n* = 26) of the strains ([Table 4](#tab4){ref-type="table"}).

3.3. Expression Patterns of the Virulence Genes and*CDR1* {#sec3.3}
---------------------------------------------------------

In nearly all of the isolates,*ALS1*,*HWP1*,*SAP4*--*SAP6*,*LIP1*--*LIP10*,*PLB1*, and*PLB2* were expressed after infection of the cell line A431, whereas*CDR1* was expressed in 20 (51.3%) and*ALS3* in 14 (35.8%) ([Table 4](#tab4){ref-type="table"}).

Fourteen distinct expression patterns of*ALS*,*HWP1*,*SAP*,*PLB*,*LIP*, and*CDR1* were identified ([Table 5](#tab5){ref-type="table"}). The most prevalent expression profile, Pattern 1, composed of 18 genes, was found in 25.6% (*n* = 10) of the strains. Pattern 2 included 20 expressed genes and was found in 18% (*n* = 7); Patterns 3 and 4, both expressing 19 genes, were detected in 12.8% (5 strains); Patterns 5 (18 genes) and 6 (19 genes) were detected in 5.1% (*n* = 2) ([Table 5](#tab5){ref-type="table"}). The following eight expression patterns (Patterns 7--14) were represented by a single strain.*CDR1* was found in eight different patterns (*n* = 20).

4. Discussion {#sec4}
=============

In this study, we isolated and identified the virulence gene expression patterns of*C. albicans* strains in 19.5% of 200 vaginal samples. VVC is a condition that affects a quarter of young women \[[@B2], [@B24]\]. The presence of*E. coli*,*Klebsiella*spp.,*S. aureus*, or*S. epidermidis*in most vaginal samples (*n* = 161) agrees with previous reports showing bacterial vaginitis as the first cause of vaginal infections \[[@B24]\].

The chronicity of VVC or recurrent episodes by*C. albicans* is due to prolonged use of antifungals, which select for resistant strains, and due to the numerous virulence genotypes that promote adhesion to epithelial cells, production of hydrolytic enzymes, colonization, and invasion \[[@B9]\]. We found that each strain isolated that carried*ALS1* (39/39) and*ALS3* (14/14) was able to express these genes in the in vitro model of infection ([Table 4](#tab4){ref-type="table"}). The frequency of expression of the*ALS* genes reported here is similar to those reported in vaginal candidiasis models \[[@B25]\]. The ALS proteins are extracellular components of the cell membrane which mediate adhesion and colonization of host cells \[[@B26], [@B27]\]. Widespread expression of these proteins in the isolated strains supports their role in infection.

All strains positive for*HWP1* (35/35) expressed this gene during infection of A431 cells ([Table 4](#tab4){ref-type="table"}). The frequency of expression is higher than results reported in*C. albicans* strains isolated from women with vaginal infection in Turkey \[[@B28]\]. The high frequency of expression of*HWP1*and the*ALS* genes found in this study ([Table 4](#tab4){ref-type="table"}) reveals the capacity of the isolated strains to cause chronic vaginal infections. This result is consistent with reports showing that the combined expression of the adhesion proteins HWP1 and ALS1--ALS3 significantly facilitates biofilm formation \[[@B29]\] and can participate in the resistance to antifungals by limiting their penetrance to the biofilm \[[@B30]\].

Likewise, all isolated strains expressed*SAP4*--*SAP6* (39/39) and almost all expressed*SAP1* (92.3%, (36/37)) ([Table 4](#tab4){ref-type="table"}). These results are similar to those previously described for*SAP* expression in VVC in humans \[[@B31]\]. The expression of*SAP4*--*SAP6* has a relevant role in pathogenesis by promoting hyphae formation \[[@B32]\] and by the inhibition of phagocytosis \[[@B33]\].

In this study, most strains expressed genes of the*LIP* family, except*LIP3*,*LIP5*, and*LIP8* ([Table 4](#tab4){ref-type="table"}). These data are consistent with those reported using an in vitro infection model of oral epithelial cells and in patient samples \[[@B34]\]. The specific role of LIP proteins in infection is unknown. However, it has been described that*LIP* family members are differentially expressed during infection in specific areas of affected mucosae \[[@B35]\].

All strains of*C. albicans* expressed*PLB1* and*PLB2* (39/39) ([Table 4](#tab4){ref-type="table"}). Recently, phospholipase activity was reported in strains of*C. albicans* and in nonalbicans strains from patients with vulvovaginal infections \[[@B36]\], as well as in different*Candida* species isolated from patients with type 2 diabetes mellitus suffering from VVC \[[@B37]\]. The elevated expression of phospholipase genes in the*C. albicans* strains isolated in this study ([Table 4](#tab4){ref-type="table"}) suggests that these genes are essential for vaginal infection by participating in the breakdown of the cell membrane, which allows the hyphae to penetrate the epithelial cell cytoplasm \[[@B7]\].

The use of azoles for the treatment of VVC over time has resulted in the selection of strains resistant to these compounds \[[@B38]\]. In this study, the association of azole resistance phenotypes (fluconazole/ketoconazole) was identified in 94.9% (*n* = 37) of the strains ([Table 3](#tab3){ref-type="table"}), whereas*CDR1* was found in only 66.6% (*n* = 26) ([Table 4](#tab4){ref-type="table"}). This gap in detection can be explained by the idea that azole resistance is not only conferred by*CDR1*, an ABC transporter, but may also be caused by the overproduction of an azole target, 14*α*-demethylase, which is encoded by*ERG11*. Other mechanisms of azole resistance are caused by mutations in*ERG11* which decrease azole affinity to this enzyme \[[@B10], [@B39]\].

Interestingly, all strains described in this study were sensitive to nystatin (*n* = 39, [Table 3](#tab3){ref-type="table"}), as also reported in other studies \[[@B40], [@B41]\]. This result suggests that nystatin can be an alternative for the treatment of vaginal infections caused by strains of*C. albicans* which are resistant to azoles \[[@B42]\]. The high frequencies of strains resistant to fluconazole and ketoconazole ([Table 3](#tab3){ref-type="table"}) can be explained by the high use of these two drugs (and clotrimazole) in Mexico, given that this is the most commonly used therapy against VVC. Our results are consistent with the observation that*Candida* species isolated in different geographical regions differ in their sensitivity to fluconazole \[[@B43]\].

In this study, we identified 14 distinct expression patterns of*ALS*,*HWP1*,*SAP*,*LIP*,*PLB*, and*CDR1* in A431 cells infected in vitro with strains of*C. albicans* ([Table 5](#tab5){ref-type="table"}). Pattern 1, comprising 18 genes, was expressed by most strains (25.6%). These findings show that, during the pathogenesis of infection, most virulence markers are expressed (in 8 of the 14 patterns). The combined expression of the azole resistance gene*CDR1* with the virulence markers indicates that these strains are highly virulent and should be treated with a nonazole therapy.

5. Conclusion {#sec5}
=============

This is the first work done in Mexico on global expression of different markers of virulence and resistance to azoles in clinical strains of*C. albicans*. The results show that the strains that infect Mexican patients suffering from VVC are highly virulent and virtually all are insensitive to azoles.
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###### 

Primers used in PCR and real-time PCR assays.

  Gene      Orientation                      Sequence 5′ to 3′
  --------- -------------------------------- -------------------------------
  rRNA      FW                               TTTATCAACTTGTCACACCAGA
  RV        ATCCCGCCTTACCACTACCG             
                                             
  *ALS1*    FW                               CCATCACTGAAGATATCACCACA
  RV        TGGAGCTTCTGTAGGACTGGTT           
                                             
  *ALS3*    FW                               CCAAGTGTTCCAACAACTGAAA
  RV        GAACCGGTTGTTGCTATGGT             
                                             
  *HWP1*    FW                               CCATGTGATGATTACCCACA
  RV        GCTGGAACAGAAGATTCAGG             
                                             
  *SAP1*    FW                               TCAATCAATTTACTCTTCCATTTCTAACA
  RV        CCAGTAGCATTAACAGGAGTTTTAATGACA   
                                             
  *SAP4*    FW                               TTATTTTTAGATATTGAGCCCACAGAAA
  RV        GCCAGTGTCAACAATAACGCTAAGTT       
                                             
  *SAP5*    FW                               AGAATTTCCCGTCGATGAGACTGG
  RV        CAAATTTTGGGAAGTGCGGGAAGA         
                                             
  *SAP6*    FW                               CCCGTTTTGAAATTAAATATGCTGATGG
  RV        GTCGTAAGGAGTTCTGGTAGCTTCG        
                                             
  *LIP1*    FW                               AGCCCAACCAGAAGCTAATGAA
  RV        TGATGCAAAAGTCGCCATGT             
                                             
  *LIP2*    FW                               GGCCTGGATTGATGCAAGAT
  RV        TTGTGTGCAGACATCCTTGGA            
                                             
  *LIP3*    FW                               TCTCACCGAGATTGTTGTTGGA
  RV        GTTGGCCATCAAATCTTGCA             
                                             
  *LIP4*    FW                               GCGTCCTGTTGCTTTCACT
  RV        ACACGGTTTGTTTTCCATTGAA           
                                             
  *LIP5*    FW                               TGGTTCCAAAAATACCGTGTT
  RV        CGACAATAGGGACGATTTGATCA          
                                             
  *LIP6*    FW                               AAGAATCTTCCGACCTGACCAA
  RV        ATATGCACCTGTTGACGTTCAAA          
                                             
  *LIP7*    FW                               AACTGATATTTGCCATGCATTAGAAA
  RV        CCATTCCCGGTAACTAGCATGT           
                                             
  *LIP8*    FW                               CAACAATTGCTAAAATCGTTGAAGA
  RV        AGGGATTTTTGGCACTAATTGTTT         
                                             
  *LIP9*    FW                               CGCAAGTTTGAAGTCAGGAAAA
  RV        CCCACATTACAATTTGGCATCT           
                                             
  *LIP10*   FW                               CACCTGGCTTAGCAGTTGCA
  RV        CCCAGCAAAGACTCATTTTATTCA         
                                             
  *PLB1*    FW                               GGTGGAGAAAGATGGCCAAAA
  RV        AGCACTTACGTTACGATGCAACA          
                                             
  *PLB2*    FW                               TGAAACCTTTGGGCGACAACT
  RV        GCCGCGCTCGTTGTTAA                
                                             
  *CDR1*    FW                               AAGAGAACCATTACCAGG
  RV        AGGAATCGACGGATCAC                
                                             
  *MDR1*    FW                               GGAGTTTAGGTGCTGT
  RV        CGGTGATGGCTCTCAA                 

###### 

Interpretive criteria of susceptibility and resistance to antifungals used in this study.

  Antifungal drugs   Zone diameter (mm)            
  ------------------ -------------------- -------- -----
  Ketoconazole       ≥30                  23--29   ≤22
  Fluconazole        ≥19                  15--18   ≤14
  Nystatin           ≥25                  17--24   ≤14

###### 

Susceptibility and resistance of *Candida albicans* strains to antifungal drugs.

  --------------------------------------------
  Antifungal drugs   Resistant\   Sensitive\
                     Number (%)   Number (%)
  ------------------ ------------ ------------
  Nystatin           0 (0)        39 (100)

  Fluconazole        37 (94.9)    2 (5.1)

  Ketoconazole       38 (97.4)    1 (2.6)
  --------------------------------------------

###### 

Percentages of detection and expression of virulence markers and azole resistance genes in *Candida albicans* strains.

  ------------------------------------
  Gene      Detection\   Expression\
            Number (%)   Number (%)
  --------- ------------ -------------
  *ALS1*    39 (100)     39 (100)

  *ALS3*    14 (35.8)    14 (35.8)

  *HWP1*    35 (89.7)    35 (89.7)

  *SAP1*    37 (94.8)    36 (92.3)

  *SAP4*    39 (100)     39 (100)

  *SAP5*    39 (100)     39 (100)

  *SAP6*    39 (100)     39 (100)

  *LIP1*    39 (100)     39 (100)

  *LIP2*    39 (100)     39 (100)

  *LIP3*    38 (97.4)    38 (97.4)

  *LIP4*    39 (100)     39 (100)

  *LIP5*    35 (89.7)    35 (89.7)

  *LIP6*    39 (100)     39 (100)

  *LIP7*    39 (100)     39 (100)

  *LIP8*    38 (97.4)    38 (97.4)

  *LIP9*    39 (100)     39 (100)

  *LIP10*   39 (100)     39 (100)

  *PLB1*    39 (100)     39 (100)

  *PLB2*    39 (100)     39 (100)

  *CDR1*    26 (66.6)    20 (51.3)

  *MDR1*    0 (0)        0 (0)
  ------------------------------------

###### 

Expression patterns of virulence genes and *CDR1* in *Candida albicans* strains.

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Pattern\   Pattern                                                                                                  Number of strains   \%
  number                                                                                                                                  
  ---------- -------------------------------------------------------------------------------------------------------- ------------------- ------
  1          *ALS1/HWP1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2*             10                  25.6

  2          *ALS1/ALS3/HWP1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2/CDR1*   7                   18.0

  3          *ALS1/ALS3/HWP1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2*        5                   12.8

  4          *ALS1/HWP1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2/CDR1*        5                   12.8

  5          *ALS1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2/CDR1*             2                   5.1

  6          *ALS1/HWP1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2/CDR1*        2                   5.1

  7          *ALS1/HWP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2*                       1                   2.5

  8          *ALS1/ALS3/HWP1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2*             1                   2.5

  9          *ALS1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2*                  1                   2.5

  10         *ALS1/HWP1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2/CDR1*             1                   2.5

  11         *ALS1/HWP1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP6/LIP7/LIP9/LIP10/PLB1/PLB2*                       1                   2.5

  12         *ALS1/HWP1/SAP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2/CDR1*        1                   2.5

  13         *ALS1/ALS3/HWP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2/CDR1*        1                   2.5

  14         *ALS1/HWP1/SAP4/SAP5/SAP6/LIP1/LIP2/LIP3/LIP4/LIP5/LIP6/LIP7/LIP8/LIP9/LIP10/PLB1/PLB2/CDR1*             1                   2.5
  ----------------------------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Jorge Garbino
